Value_Investor
2 weeks ago
VINC just released a Good News in After-Hours after the market close --- see the link below!
https://ih.advfn.com/stock-market/NASDAQ/vincerx-VINC/stock-news/95460166/form-8-k-current-report
On February 11, 2025, Vincerx Pharma, Inc. (the “Company”) received written notice (the “Compliance Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on the Nasdaq Capital Market maintain a minimum bid price of $1.00 per share. Nasdaq notified the Company in the Compliance Notice that, from January 28, 2025 to February 10, 2025, the closing bid price of the Company’s common stock had been $1.00 per share or greater and, accordingly, the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2) and that the matter was now closed.
The POSITIVE Huge Book Value is $5.43 a share vs. the stock is trading at Ridiculous-Low price levels $1.28 now, LOL! Easy to surge over January 28's Premarket-High $3.35 which is still far below its Book Value!
Note, on January 16, 2025, VINC did bounce to $3.502 in the After-Hours session!
Every common share of VINC is worthy $6.323 based on the Minimal $14.16 Millions dollars of Buy-Out deal and 2,239,580 shares Super Tiny OS count!
https://www.otcmarkets.com/filing/html?id=18164033&guid=o30-knmVG-GTh3h
This Diamond-In-Rough is at Hyper Oversold status --- from 12/30/2024's $10.4 to New Bottom $1.18!
So, this Hidden Gem is Super Undervalued now!
Value_Investor
3 weeks ago
It is Super Hard to understand why this Hidden Gem has $5.4286 per share Huge POSITIVE Book Value but it is trading at such Ridiculous-Low or Huge Discount price levels $1.3x ~ $1.4x?
If I had $3,045,828.80 cash at hand then I'm willing to Buy-Out the Entire OS at current Huge Discount Dirt Cheap price $1.36 because 2,239,580 x $1.36 = $3,045,828.80!
georgie18
4 weeks ago
VINC...$1.69...🥳
georgie18
Member Level
Re: None
Saturday, February 01, 2025 3:12:37 PM
Post#
31347
of 31358
VINC...$1.58...🥳...https://schrts.co/xpMPMrhfh ...Bullish Deliberation Block Reversal Pattern...on this Oversold Chart... 2million Range Float Post Split...
georgie18
Member Level
Re: georgie18 post# 31
Wednesday, January 29, 2025 8:28:50 AM
Post#
51
of 54
VINC...$2.11 ...Post Split...🥳... Vincerx-Pharma-Inc-and-Oqory-Inc-Highlight-Promising-Data-for-Oqory-s-TROP2-Antibody-Drug-Conjugate-OQY-3258.html" rel="nofollow noopener noreferrer ugc" target="_blank">https://www.globenewswire.com/news-release/2025/01/29/3017128/0/en/Vincerx-Pharma-Inc-and-Oqory-Inc-Highlight-Promising-Data-for-Oqory-s-TROP2-Antibody-Drug-Conjugate-OQY-3258.html
georgie18
Member Level
Re: georgie18 post# 387642
Friday, December 27, 2024 4:35:45 PM
Post#
387643
of 389318
VINC...40s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 29
Friday, December 27, 2024 4:19:41 PM
Post#
30
of 30
VINC....1946...🥳...Alerted at 2954...PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications.
Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%. The transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing and, as a condition to the closing of the merger, completion of a concurrent offering of Vincerx equity securities of at least $20 million. Additionally, Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches, approximately $1,000,000 of which was funded today through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 of which will be funded on or prior to January 31, 2025. The merger is subject to customary closing conditions, including due diligence, regulatory approvals, negotiation of a definitive merger agreement, stockholder approval from both parties, completion of the minimum $20 million financing, and the continued listing of Vincerx's common stock on Nasdaq.
georgie18
Member Level
Re: georgie18 post# 386297
Monday, December 09, 2024 4:01:30 PM
Post#
386750
of 387642
VINC...2194...added here today...🥳
georgie18
Member Level
Re: None
Monday, December 02, 2024 9:42:03 AM
Post#
28
of 28
VINC...2954...🥳...Trying to Reverse here to the Upside...
georgie18
4 weeks ago
VINC...$1.58...🥳...https://schrts.co/xpMPMrhfh ...Bullish Deliberation Block Reversal Pattern...on this Oversold Chart... 2million Range Float Post Split...
georgie18
Member Level
Re: georgie18 post# 31
Wednesday, January 29, 2025 8:28:50 AM
Post#
51
of 54
VINC...$2.11 ...Post Split...🥳... https://www.globenewswire.com/news-release/2025/01/29/3017128/0/en/Vincerx-Pharma-Inc-and-Oqory-Inc-Highlight-Promising-Data-for-Oqory-s-TROP2-Antibody-Drug-Conjugate-OQY-3258.html
georgie18
Member Level
Re: georgie18 post# 387642
Friday, December 27, 2024 4:35:45 PM
Post#
387643
of 389318
VINC...40s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 29
Friday, December 27, 2024 4:19:41 PM
Post#
30
of 30
VINC....1946...🥳...Alerted at 2954...PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications.
Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%. The transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing and, as a condition to the closing of the merger, completion of a concurrent offering of Vincerx equity securities of at least $20 million. Additionally, Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches, approximately $1,000,000 of which was funded today through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 of which will be funded on or prior to January 31, 2025. The merger is subject to customary closing conditions, including due diligence, regulatory approvals, negotiation of a definitive merger agreement, stockholder approval from both parties, completion of the minimum $20 million financing, and the continued listing of Vincerx's common stock on Nasdaq.
georgie18
Member Level
Re: georgie18 post# 386297
Monday, December 09, 2024 4:01:30 PM
Post#
386750
of 387642
VINC...2194...added here today...🥳
georgie18
Member Level
Re: None
Monday, December 02, 2024 9:42:03 AM
Post#
28
of 28
VINC...2954...🥳...Trying to Reverse here to the Upside...
georgie18
1 month ago
VINC...$2.11 ...Post Split...🥳... https://www.globenewswire.com/news-release/2025/01/29/3017128/0/en/Vincerx-Pharma-Inc-and-Oqory-Inc-Highlight-Promising-Data-for-Oqory-s-TROP2-Antibody-Drug-Conjugate-OQY-3258.html
georgie18
Member Level
Re: georgie18 post# 387642
Friday, December 27, 2024 4:35:45 PM
Post#
387643
of 389318
VINC...40s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 29
Friday, December 27, 2024 4:19:41 PM
Post#
30
of 30
VINC....1946...🥳...Alerted at 2954...PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications.
Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%. The transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing and, as a condition to the closing of the merger, completion of a concurrent offering of Vincerx equity securities of at least $20 million. Additionally, Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches, approximately $1,000,000 of which was funded today through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 of which will be funded on or prior to January 31, 2025. The merger is subject to customary closing conditions, including due diligence, regulatory approvals, negotiation of a definitive merger agreement, stockholder approval from both parties, completion of the minimum $20 million financing, and the continued listing of Vincerx's common stock on Nasdaq.
georgie18
Member Level
Re: georgie18 post# 386297
Monday, December 09, 2024 4:01:30 PM
Post#
386750
of 387642
VINC...2194...added here today...🥳
georgie18
Member Level
Re: None
Monday, December 02, 2024 9:42:03 AM
Post#
28
of 28
VINC...2954...🥳...Trying to Reverse here to the Upside...
Value_Investor
2 months ago
Liquidate the Pos Scam ASAP! Because there are A Series Of Bad News about the company! Here are the seventh, eighth, and nineth Bad news for VINC:
"SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates VINC, MHLD, NEUE on Behalf of Shareholders" --- see the link below for the details.
https://www.otcmarkets.com/stock/VINC/news/story?e&id=3095233
"Kuehn Law Encourages VINC, NEUE, GETY, and CLBR Investors to Contact Law Firm" --- see the link below for the details.
https://www.otcmarkets.com/stock/VINC/news/story?e&id=3098961
"Up to 1:20 Big R/S" --- see the link below for the details.
https://www.otcmarkets.com/filing/html?id=18036191&guid=Qs0-kKDmXUvnJth
"16,356,210 shares of Huge New FREE dilutions" --- see the link below for the details.
https://www.otcmarkets.com/filing/html?id=18074105&guid=Qs0-kKDmXUvnJth
So, we should see A Series Of New 52-Week-Lows until VINC hits the Final Bottom $0.025...
Are you kidding? "The next Misrosoft|? No way! The best situation is to avoid to file the BANKRUPTCY! I wish "No Bankruptcy" here so that we could see a "Dead-Cat Bounce" sometime this year!
Value_Investor
2 months ago
Liquidate the Pos Scam ASAP! Because there are A Series Of Bad News about the company! Here are the fourth, fifth, and sixth Bad news for VINC:
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JWN, VINC, OMIC on Behalf of Shareholders" --- see the link below for the details.
https://www.otcmarkets.com/stock/VINC/news/story?e&id=3089437
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VINC, NEUE, ZUO on Behalf of Shareholders" --- see the link below for the details.
https://www.otcmarkets.com/stock/VINC/news/story?e&id=3092088
"VINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc. - VINC" --- see the link below for the details.
https://www.otcmarkets.com/stock/VINC/news/story?e&id=3093920
Value_Investor
2 months ago
Liquidate the Pos Scam ASAP! Because there are A Series Of Bad News about the company! Here are the first, second, and third Bad news for VINC:
"Shareholder Alert: Ademi LLP Investigates Whether Vincerx Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders" --- see the link below for the details.
https://www.otcmarkets.com/stock/VINC/news/story?e&id=3087853
"VINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Vincerx Pharma, Inc. Is Fair to Shareholders" --- see the link below for the details.
https://www.otcmarkets.com/stock/VINC/news/story?e&id=3087906
"STOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger - VINC, VCSA, MRNS, MHLD" --- see the link below for the details.
https://www.otcmarkets.com/stock/VINC/news/story?e&id=3089161
georgie18
2 months ago
VINC...40s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 29
Friday, December 27, 2024 4:19:41 PM
Post#
30
of 30
VINC....1946...🥳...Alerted at 2954...PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications.
Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%. The transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing and, as a condition to the closing of the merger, completion of a concurrent offering of Vincerx equity securities of at least $20 million. Additionally, Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches, approximately $1,000,000 of which was funded today through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 of which will be funded on or prior to January 31, 2025. The merger is subject to customary closing conditions, including due diligence, regulatory approvals, negotiation of a definitive merger agreement, stockholder approval from both parties, completion of the minimum $20 million financing, and the continued listing of Vincerx's common stock on Nasdaq.
georgie18
Member Level
Re: georgie18 post# 386297
Monday, December 09, 2024 4:01:30 PM
Post#
386750
of 387642
VINC...2194...added here today...🥳
georgie18
Member Level
Re: None
Monday, December 02, 2024 9:42:03 AM
Post#
28
of 28
VINC...2954...🥳...Trying to Reverse here to the Upside...
georgie18
2 months ago
VINC....1946...🥳...Alerted at 2954...PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications.
Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%. The transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing and, as a condition to the closing of the merger, completion of a concurrent offering of Vincerx equity securities of at least $20 million. Additionally, Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches, approximately $1,000,000 of which was funded today through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 of which will be funded on or prior to January 31, 2025. The merger is subject to customary closing conditions, including due diligence, regulatory approvals, negotiation of a definitive merger agreement, stockholder approval from both parties, completion of the minimum $20 million financing, and the continued listing of Vincerx's common stock on Nasdaq.
georgie18
Member Level
Re: georgie18 post# 386297
Monday, December 09, 2024 4:01:30 PM
Post#
386750
of 387642
VINC...2194...added here today...🥳
georgie18
Member Level
Re: None
Monday, December 02, 2024 9:42:03 AM
Post#
28
of 28
VINC...2954...🥳...Trying to Reverse here to the Upside...
tw0122
5 months ago
VINC .84 + 20% …05:05 PM EDT, 10/07/2024 (MT Newswires) -- Vincerx Pharma (VINC) said its VIP943 leukemia drug showed "promising safety and tolerability," achieving two complete responses to date in a phase 1 dose-escalation study
The VIP943 antibody-drug conjugate is being evaluated in relapsed/refractory acute myeloid leukemia, higher-risk myelodysplastic syndrome and B-cell acute lymphoblastic leukemia, the company said Monday in a statement.
Another data update is expected by the end of the year, the company said.
In an update on VIP236 being evaluated in a first-in-human, phase 1 dose-escalation study as a monotherapy in patients with advanced solid tumors, the company said it intends to pursue a strategic partner to "champion its future development" in order to focus on VIP943.
Vincerx expects a cash runway into early 2025.
Shares of the company jumped 15% in after-hours activity.
Price: 0.8000, Change: +0.10, Percent Change: +
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
glenn1919
2 days ago
Monksdream
2 weeks ago
SmokeSignals
2 months ago
Hot Features
Premium
